Head-to-head · free
Ascentage Pharma Group International vs Arbutus Biopharma Corp
AAPG vs ABUS — return on capital, cash generation, margins and balance sheet side by side.
AAPG
1 / 3
measures where AAPG leads
ABUS
2 / 3
measures where ABUS leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | AAPG | ABUS · FY2025 |
|---|---|---|
| Revenue | — | $14.1M |
| Net income | — | (33.5M) |
| Revenue growth (yearly, multi-year) | — | 6.4% |
| Free cash flow | — | (39.6M) |
| Free cash flow margin | — | -281.5% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -156.5% | -38.5% |
| Gross margin | 91.5% | — |
| Operating margin | -208.6% | -192.1% |
| Net debt / EBITDA | 0.46x | 0.48x |
Figures are as reported by each company; latest fiscal year shown.
Where Arbutus Biopharma Corp's cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free